Compare Endeavour Silver Corp (EXK) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Endeavour Silver Corp vs Johnson & Johnson — how do they compare? Endeavour Silver Corp trades at $8.73 (market cap $2.54B), while Johnson & Johnson trades at $260.64 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 243.3× Endeavour Silver Corp's market cap, and Johnson & Johnson pays a 2.09% dividend while Endeavour Silver Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Endeavour Silver Corp for 25 Days and Johnson & Johnson for 129 Days on average.
| EXK | JNJ | |
|---|---|---|
Market Cap | $2.54B | $618.09B |
Volume | 7,077,330 | 6,050,983 |
Sector | Basic Materials | Health |
52-Week High | $14.12 | $278.43 |
52-Week Low | $7.07 | $186.00 |
Typical Hold Time | 25 Days | 129 Days |
Enterprise Value | $2.54B | $646.37B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Endeavour Silver (EXK) trades at $8.77, up 5.41% today, showing mixed technical signals with a bearish moving average trend but neutral oscillators. The company reported strong Q1 2026 earnings beat but missed Q2 expectations, with revenue projected to grow from $468M in 2025 to $737M in 2026. Recent developments include operational progress at Terronera mine and resolution of blockade issues, while maintaining a 78.57% analyst buy rating.
EXK presents growth potential through mine expansions and favorable silver prices, but faces execution risks from operational disruptions and negative 2025 net income. The stock's high P/E ratio of 42.85 suggests premium valuation, requiring careful monitoring of production targets and cost management for sustained profitability improvement.
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
